Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Becton, Dickinson and Company    BDX

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/15/2020 10/16/2020 10/19/2020 10/20/2020 10/21/2020 Date
235.01(c) 236.99(c) 237.38(c) 236.26(c) 236.4(c) Last
1 144 140 1 055 055 1 121 642 830 544 1 174 490 Volume
+0.56% +0.84% +0.16% -0.47% +0.06% Change
More quotes
Financials (USD)
Sales 2020 16 820 M - -
Net income 2020 1 110 M - -
Net Debt 2020 15 059 M - -
P/E ratio 2020 60,3x
Yield 2020 1,45%
Sales 2021 18 795 M - -
Net income 2021 2 403 M - -
Net Debt 2021 12 743 M - -
P/E ratio 2021 23,8x
Yield 2021 1,60%
Capitalization 68 525 M 68 525 M -
EV / Sales 2020 4,97x
EV / Sales 2021 4,32x
Nbr of Employees 70 093
Free-Float 79,4%
More Financials
Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (52.4%): surgical instruments (71.6% of net sales), pharmaceutical systems (16.2%), and diabetes care products (12.2%); - diagnostic materials (24.9%): automated systems for blood testing, mycobacteria... 
More about the company
Notations Surperformance© of Becton, Dickinson and Company
Trading Rating : Investor Rating :
More Ratings
All news about BECTON, DICKINSON AND COMPANY
07:50aBECTON DICKINSON AND : Names Patrick Kaltenbach Chief Technology Officer
DJ
06:58aBECTON DICKINSON AND : BD Announces Executive Leadership Appointments
PR
10/21Abbott says COVID-19 test demand to grow in 2021
RE
10/21BECTON DICKINSON AND : CerTest Biotec and BD Announce CE Mark for Combination CO..
PR
10/19BECTON DICKINSON AND : BD Announces Assay for Immune Assessment of COVID-19 Pati..
AQ
10/15Roche diagnostics business surges as COVID-19 infections rise
RE
10/15Roche diagnostics business surges as COVID-19 infections rise
RE
10/14Healthineers launches rapid coronavirus antigen test, sees tight supply
RE
10/13Countries turn to rapid antigen tests to contain second wave of COVID-19
RE
10/09BECTON DICKINSON AND : Trump Administration Orders Nevada to Allow Rapid Covid-1..
DJ
10/09Nevada's ban on Quidel and Becton Dickinson COVID-19 tests violates law -HHS ..
RE
10/09Nevada's prohibition of Quidel, Becton Dickinson's COVID-19 tests violates la..
RE
10/07BD MARKS 25 YEARS WITH MERCY SHIPS : Donates $1M to support launch of world's la..
PR
10/05BECTON DICKINSON & CO : Amendments to Articles of Inc. or Bylaws; Change in Fisc..
AQ
10/05BECTON DICKINSON AND : BD Granted FDA 510(k) Clearance for BD FACSLyric™ F..
PR
More news
News in other languages on BECTON, DICKINSON AND COMPANY
08/03BECTON, DICKINSON AND COMPANY : Veröffentlichung des Quartalsergebnisses
08/03BECTON, DICKINSON AND COMPANY : publication des résultats trimestriels
07/06BECTON, DICKINSON AND COMPANY : Lancement du test rapide Covid-19 aux Etats-Unis
05/04BECTON, DICKINSON AND COMPANY : Veröffentlichung des Halbjahresergebnisses
05/04BECTON, DICKINSON AND COMPANY : publication des résultats semestriels
More news
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 276,00 $
Last Close Price 236,40 $
Spread / Highest target 26,9%
Spread / Average Target 16,8%
Spread / Lowest Target 7,87%
EPS Revisions
Managers
NameTitle
Thomas E. Polen President, Chief Executive Officer & Director
Vincent A. Forlenza Executive Chairman
Christopher R. Reidy EVP, Chief Financial & Administrative Officer
John A. DeFord Chief Technology Officer & Executive VP
William R. Sigmund Chief Medical Officer & EVP
Sector and Competitors
1st jan.Capitalization (M$)
BECTON, DICKINSON AND COMPANY-13.08%68 525
ABBOTT LABORATORIES21.95%187 552
MEDTRONIC PLC-3.72%146 850
HOYA CORPORATION16.94%43 777
BAXTER INTERNATIONAL INC.-2.25%41 379
DEXCOM, INC.77.31%37 133